Latest News
Evrysdi Risdiplam Tablet Is Now Approved For Broader Use In SMA
We’re excited to share an important update for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved a label expansion for Evrysdi® (risdiplam) tablets, […]
Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our […]
Biogen Announces Results from the Phase 2/3 DEVOTE Study
Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living […]